Cg Oncology, INC 10-Q quarterly reports

CG Oncology, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026, detailing increased operating expenses and net losses, alongside substantial cash reserves and ongoing clinical development for its bladder cancer treatment.

CG Oncology reports Q1 2026 financial results, highlighting a strong cash position of $1.08 billion and continued clinical progress for its lead bladder cancer candidate.

CG Oncology announced positive 24-month Phase 3 clinical trial results for cretostimogene in bladder cancer and acquired Biovire to enhance manufacturing capabilities, despite increased net losses.

CG Oncology reported increased R&D expenses and net losses in Q2 2025, but highlighted significant clinical progress for cretostimogene and a major legal win against ANI Pharmaceuticals.

CG Oncology's Q1 2025 results show increased R&D spending and a net loss, but the company is progressing with clinical trials and anticipates a BLA submission in the second half of 2025.

CG Oncology's third quarter 2024 results show increased spending on research and development, offset by gains from interest income, following a successful IPO.

CG Oncology's second quarter 2024 results show increased spending on research and development following their recent IPO, with a net loss of $18.9 million.

CG Oncology's first quarter 2024 results show a significant increase in cash and marketable securities following its IPO, alongside increased research and development spending.